Nathalie Belmonte

Sr VP Research & Translation at Quell Therapeutics

Nathalie is SVP Research & Translation at Quell Tx, developing CAR-Treg therapy. Before joining Quell Tx, Nathalie served as COO at Promethera Biosciences developing MSC-based therapy. Prior to that, she served as VP R&D at TxCell developing Treg cell-based therapy. She holds a PhD in Cell and Molecular Biology followed by a post-doctoral position at the Telethon Institute for Gene Therapy (TIGET) in Milan.